Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24823659 | 0.85 | AOC3 (0.32) | AOC3TYK2CHRM2CHRM3BRD4 | |
| SCHEMBL24823948 | 0.84 | AOC3 (0.32) | AOC3TYK2CHRM2CHRM3BRD4 | |
| SCHEMBL24823030 | 0.82 | CHRM2 (0.36) | ALOX5APFEN1HSD17B10CHRM2CHRM3 | |
| SCHEMBL30079527 | 0.81 | AOC3 (0.30) | AOC3 | |
| SCHEMBL24823037 | 0.81 | AOC3 (0.30) | AOC3 | |
| SCHEMBL24823026 | 0.80 | ALOX5AP (0.31) | ALOX5APFEN1 | |
| SCHEMBL24823671 | 0.79 | ALOX5AP (0.39) | ALOX5APFEN1BRD4BRD3 | |
| SCHEMBL30079652 | 0.79 | ALOX5AP (0.39) | ALOX5APFEN1BRD4BRD3 | |
| SCHEMBL24822802 | 0.77 | ALOX5AP (0.35) | AOC3ALOX5APFEN1TYK2CHRM2 | |
| SCHEMBL24776416 | 0.74 | PIK3CD (0.43) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337648-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20240124421-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-04-18 | — | — | US | disclosed |
| EP-4337648-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11884650-B2 | Substituted heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| CN-117355514-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-08 | — | — | US | disclosed |
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-08 | — | — | US | disclosed |
| WO-2022241174-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884650-B2 | Substituted heterocyclic compounds | TYK2, JAK2, STAT3 | AOC3 1933/4885ALOX5AP 3808/4885FEN1 4033/4885 |
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | AOC3 1933/4885ALOX5AP 3808/4885FEN1 4033/4885 |
| US-20240124421-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | AOC3 1933/4885ALOX5AP 3808/4885FEN1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.